Hemosure, Inc. has continuously researched, developed, and produced rapid test systems for detecting gastrointestinal disorders. Hemosure has not only revolutionized the medical industry, but has also set new industry standards and guidelines with its CLIA waived Hemosure® Immunochemical Fecal Occult Blood Test (IFOBT), a trade name recognized worldwide in Immunological Fecal Occult Blood Testing (FIT). One of the more notable considerations is there are no drug or diet restrictions.

Simply stated, Hemosure® IFOBT is a rapid, convenient and odorless qualitative, sandwich dye conjugate immunoassay for the determination of human hemoglobin in feces; typically used for Colorectal Cancer screening. Colorectal Cancer, when discovered at its earliest stages, is the most preventable and curable of all cancers. Routine Colorectal Screening (CRC) is extremely important, which is why Hemosure is dedicated to educating ALL and extending the lowest possible cost.

In February 2009, the American College of Gastroenterology, with a dramatic change of direction, released its first update in CRC Guidelines in almost a decade. The new ACG Guidelines state:

"The American College of Gastroenterology supports the joint guideline recommendation that older guaiac-based fecal occult blood tests be abandoned as a method for CRC screening...the ACG recommends the FIT as the preferred cancer detection test."
(Reprinted by permission from Macmillan Publishers Ltd: The American Journal of Gastroenterology (2320970223955) copyright (2009)

To view complete ACG article please visit:

Hemosure has become the fastest growing IFOBT and taken its place as an industry leader. Even so, Hemosure maintains its goal to be the most cost effective and offer the most competitive pricing by joining multiple Group Purchasing Organizations (GPO). As of May 1, 2011 Hemosure IFOBT and Amerinet Choice GPO entered into a three-year agreement (contract number VL10050) to make the entire Hemosure product line available to all Amerinet GPO members. Additionally, as of June 1, 2011 Hemosure IFOBT and Novation GPO entered into a separate three-year agreement (contract number LB01228) to make the entire Hemosure product line available to all Novation GPO members. Finally, HealthTrust Purchasing Group (HPG) has made Hemosure available to its membership on the HPG Advantage Trust contract. Currently, this special pricing is available through HPG’s distribution alliances with Cardinal Health, Fisher Healthcare and Henry Schein. Please contact your supplier for details.

Hemosure’s further advancements and success center on improving our products and supplying various packaging to fit the needs of every customer. This is systematically executed by extensive marketing and close interaction with end-users. More, Hemosure ensures quality customer satisfaction by providing an experienced, well informed Implementation Team and strong Sales Force. Hemosure offers free marketing materials, samples, evaluation kits, and in-service training—all of which are key in understanding the concept and products.

We are pleased to offer you these tools, and more, and together we can move the health care industry forward in the winnable battle against colorectal cancer.
Good luck and best wishes from your friends at Hemosure!